DisperSol and Catalent Announce Manufacturing Collaboration

Article

DisperSol and Catalent announce manufacturing collaboration to accelerate DisperSol’s pharmaceutical production.

On August 2, 2021, DisperSol Technologies and Catalent announced a strategic manufacturing collaboration aimed at accelerating the production of various DisperSol pharmaceutical products.

DisperSol’s KinetiSol technology manufacturing line will be installed at Catalent's oral solids development and manufacturing facility in Somerset, NJ. This technology is designed to turn molecules with great clinical promise but poor bioavailability into viable medicine.

Per the agreement, DisperSol will provide the KinetiSol technology while Catalent will provide staff for the development, scale-up, and commercial stages of KinetiSol product creation.

“This strategic collaboration with Catalent is integral to our company as we now move into late clinical-stage development and commercial-scale manufacturing of our products,” said DisperSol CEO Edward M. Rudnic in a press release. “The commercial amorphous solid dispersion manufacturing expertise of Catalent’s team and their globally accredited quality systems make them a perfect partner for DisperSol.”

Source: Catalent

Recent Videos
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content